Care pathway, site of service, and what is already in the room — feline ckd subcutaneous fluid therapy

1. Summary

The domain dossier's Section 2 already sketches the basic shape of this pathway — clinic-based diagnosis and training, then owner-administered fluids at home — from the same 2018 US-majority owner survey this report also draws on; this report goes one level deeper into what is actually in the room once that transition happens. Diagnosis and staging happen inside ordinary general/primary-care veterinary practice, not a referral-only workflow, at least for the population sampled by this domain's own risk-factor case-control study [2]. Once therapy starts, the owner is nearly always the one who gives the injection — not a veterinary technician or family member — using an unremarkable kit (a hanging fluid bag, a giving set and a hypodermic needle) that is largely reused across sessions rather than replaced as a single-use item, and none of that kit is FDA device-registered specifically for this use: devices intended solely for veterinary purposes are exempt from establishment registration by name [4]. Guideline-recommended recheck frequency for stable CKD patients (every two to three months or more often) is not what non-US practitioner and caregiver surveys report actually happening, though the two survey types measure "compliance" differently and are not directly comparable. No US-specific study of clinic-visit frequency, technician-versus-veterinarian time allocation, or a referral-versus-general-practice placement split for this pathway was located in this pass.

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

Where in the pathway a cat with CKD is seen and staged

The case-control study that measured this domain's own risk-factor profile drew its 1,230 CKD-diagnosed cats and 1,230 age-matched controls "from the medical records of cats brought to 755 primary care veterinary hospitals" in the United States [2]. That is a sampling frame, not a population-level site-of-service statistic, but it is the only US source located this pass that says anything at all about where CKD diagnosis actually happens, and it points at ordinary general practice rather than a referral-only workflow [2][single-source]. The guideline most directly tied to this domain, the 2016 ISFM Consensus Guidelines, is likewise written for practitioners generally rather than as a referral-only protocol, describing a staging and monitoring pathway built on routine in-clinic tools (serum creatinine, urine specific gravity, blood pressure, urine protein:creatinine ratio) that any general practice already has [3][single-source].

Who actually gives the injection, and who taught them

In the 2018 survey of 468 owners of cats with CKD (352 of 468, 75%, US-based; the remainder mostly UK, Australian and Canadian), a veterinarian was reported as the one who recommended starting subcutaneous fluids in 84% of cases (n=334) versus an owner-initiated request in 14% (n=58) [1][single-source]. Once therapy is underway, the owner is also usually the one who gives the injection: among the 399 owners actively administering fluids, 90% (n=360) said they gave the fluids themselves, 15% (n=59) had a family member give them, 5% (n=18) had a veterinary technician give them, and 3% (n=12) had a veterinarian give them — categories that plainly overlap (an owner may share the task with a family member on different days), which is why the percentages do not sum to 100% [1][single-source].

What is physically in the room: site, volume, frequency and consumables

The same survey is the only source located this pass that describes the mechanics of a single administration event in any numerical detail. Injection site was interscapular ("between the shoulder blades") for 81% of administering owners (n=322 of 399), with the remaining 19% (n=77) using another location [1][single-source]. Volume per session clustered around 100 mL, reported by 52% (n=207 of 399), with 75 mL reported by 12% (n=47), 150 mL by 11% (n=43), 50 mL by 10% (n=39), and some other amount by 16% (n=63) [1][single-source]. Frequency ranged from twice daily (9%, n=37) to once daily (39%, n=156) to three-to-four times weekly (30%, n=121) to one-to-two times weekly (14%, n=57) [1][single-source]. A single session took under 5 minutes for 52% of respondents (n=206), 6–10 minutes for 34% (n=137), and 11–15 minutes for 9% (n=36) [1] [single-source]. Consumables are largely reused rather than treated as single-use: more than 90% of owners (n=364) reported changing the needle after every administration, while about 9% (n=35) reused a needle, and 96% (n=382) reported reusing the same bag of fluids across multiple sessions [1][single-source]. None of this equipment carries an FDA device clearance specific to this indication, and none is required to: 21 CFR 807.65(b) exempts "a manufacturer of devices to be used solely for veterinary purposes" from device-establishment registration outright [4].

Monitoring cadence: recommended versus achieved, and the caregiver's own report

A 2023 questionnaire study of 409 Portuguese veterinary practitioners found 70.9% (n=290) would recommend rechecking a stable CKD patient every 2–3 months or more often, but only 35.7% (n=146) reported actually being able to achieve that frequency, attributing the shortfall to "owners' constraints" [5][single-source]. A separate 2025 questionnaire study of 405 Portuguese caregivers of cats with CKD reported that 93.1% (n=377) "complied with the recommended monitoring frequency" [6][single-source] — a caregiver self-report of adherence to whatever frequency their own veterinarian actually recommended, not a measurement against the guideline's 2–3-month benchmark, so the two figures describe different things and should not be read as contradicting one another. The same caregiver study reported that subcutaneous fluid therapy specifically was being administered at home by 205 of 405 respondents (50.6%) [6][single-source]. A 2025 UK survey of 100 owners of cats with CKD, while not quantifying visit frequency, reported high rates of owner-reported anxiety (99%) and disrupted daily routine (66% "since their cat was diagnosed"), and concluded that "veterinary professionals, including veterinary nurses," may have a role in "providing greater education and support" to owners of cats with CKD [7][single-source] — the only source located this pass that names veterinary nurses/technicians specifically as a potential second point of contact in this pathway, distinct from the veterinarian.

What a general fluid-therapy guideline says, and what it does not

The 2024 AAHA Fluid Therapy Guidelines for Dogs and Cats exist as a peer-reviewed practice guideline (its abstract states the goal is to help "veterinary professionals safely and effectively prescribe and administer fluid therapy for canine and feline patients" across resuscitation, rehydration and maintenance uses) [8][single-source · paywalled]. Its full text was not retrieved this pass — a direct fetch of the publisher's own article page returned an HTTP 403 — so nothing beyond the general abstract content above is reported here; the abstract itself is not specific to feline CKD or to the home/clinic site-of-service question.

4. Sources

[1] Cooley CM, Quimby JM, Caney SM, Sieberg LG. "Survey of owner subcutaneous fluid practices in cats with chronic kidney disease." Journal of Feline Medicine and Surgery (published 2018-10, day not given in the PubMed record; accessed 2026-09-01). PMID 28948902 — https://pmc.ncbi.nlm.nih.gov/articles/PMC11129241/ [peer-reviewed] [2] "Risk factors associated with the development of chronic kidney disease in cats evaluated at primary care veterinary hospitals." Journal of the American Veterinary Medical Association (published 2014, month not given in the PubMed record; accessed 2026-09-01). PMID 24432964 — https://pubmed.ncbi.nlm.nih.gov/24432964/ [peer-reviewed] [3] Sparkes AH, et al. "ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease." Journal of Feline Medicine and Surgery (published 2016, month not given in the PubMed record; accessed 2026-09-01). PMID 26936494 — https://pubmed.ncbi.nlm.nih.gov/26936494/ [guideline] [4] Exemptions for device establishments — Code of Federal Regulations, Title 21, §807.65(b) (eCFR, current issue 2026-08-27; accessed 2026-09-01). 21 CFR 807.65 — https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-807/subpart-B/section-807.65 [federal-registry] [5] "Clinical management of feline chronic kidney disease in Portugal: a questionnaire-based study." Journal of Feline Medicine and Surgery (published 2023, month not given in the PubMed record; accessed 2026-09-01). PMID 37987623 — https://pubmed.ncbi.nlm.nih.gov/37987623/ [peer-reviewed] [6] "Caregivers' perspectives on feline chronic kidney disease in Portugal: a questionnaire-based study." Journal of Feline Medicine and Surgery (published 2025-12, day not given in the PubMed record; accessed 2026-09-01). PMID 41398709 — https://pubmed.ncbi.nlm.nih.gov/41398709/ [peer-reviewed] [7] "Owners' experiences of caring for cats with chronic kidney disease in the UK." Journal of Feline Medicine and Surgery (published 2025-04, day not given in the PubMed record; accessed 2026-09-01). PMID 40235283 — https://pubmed.ncbi.nlm.nih.gov/40235283/ [peer-reviewed] [8] "2024 AAHA Fluid Therapy Guidelines for Dogs and Cats." Journal of the American Animal Hospital Association (published 2024-07-01; accessed 2026-09-01). PMID 38885492 — https://pubmed.ncbi.nlm.nih.gov/38885492/ [guideline]

5. Sourcing & Gaps

Well established: Nothing in this report rests on two independent sources agreeing on the same specific quantity; every number above is reported by exactly one primary source and is marked [single-source] in Section 3. The general framing that diagnosis and management sit inside ordinary general practice rather than a referral-only workflow is supported by two different documents ([2]'s sampling frame and [3]'s general-practitioner-oriented guideline design), but they support that framing separately rather than jointly stating it as a fact, so it is not treated as a plainly-stated multi-source line — see the [inference] entry below.

Thin: Every quantity in Section 3 carries [single-source]: the recommender/administrator split, injection site, volume, frequency, session duration and consumable-reuse rates (all [1]); the primary-care sampling frame (2); the guideline's general-practice design (3); the Portuguese practitioner recheck-compliance figures (5); the Portuguese caregiver monitoring-compliance and home-administration figures (6); the UK caregiver-burden and veterinary-nurse-role finding (7); and the AAHA guideline's existence and general scope (8), which additionally carries [paywalled] because its full text was not reachable.

Rescoped from class 3: None in this report. The domain dossier already records one relevant class-3 question and its twin — whether general-practice veterinarians (versus referral surgeons) would place an implanted fluid port, rescoped to "what fraction of the closest analog implant procedures are performed in general practice versus referral," which the dossier already notes remains unanswered — and this report did not reopen or attempt that question; nothing new posed here needed rescoping.

Out of scope: CPT-coded office-visit and client-education descriptors (AMA-licensed) were not retrieved even though they would sharpen the "time already spent in the room" picture. Any veterinary-specific claims database or aggregated-EHR dataset (Banfield/Mars, VetCompass-US) that might give a population-level site-of-service or visit-frequency figure was not attempted — these require a paid licence per this repo's veterinary-data scope exclusion.

Not searched vs. not found: Not found despite a direct query: connectors trials --condition "feline chronic kidney disease" returned zero records over the full window searched — confirmed empty, not merely unsearched, and consistent with ClinicalTrials.gov being a human-subjects registry with no veterinary jurisdiction. Not searched this pass: a staffing- or time-motion study of veterinary-technician workload specific to teaching owners subcutaneous fluid technique. Read but excluded from Section 4: IRIS's own current "Treatment Recommendations for Cats (2026)" PDF was fetched in full this pass (via https://www.iris-kidney.com/s/IRIS_CAT_Treatment_Recommendations_-2026.pdf, which redirected to a Squarespace-hosted file, retrieved 2026-09-01) and read completely. It states that clinical dehydration should be corrected with isotonic polyionic fluids "IV or SQ" at every CKD stage and that Stage 3–4 patients "may require maintenance fluids administered routinely to maintain hydration," with a footnote specifying maintenance-fluid composition (low sodium, 30–40 mmol/l; added potassium, about 13 mmol/l; e.g. Normosol-M or 5% dextrose plus 0.18% NaCl with added KCl) — but it does not itself state a specific subcutaneous-fluid volume-and-frequency dosing schedule, unlike what a secondary source had characterized to the domain dossier's own §4. This document is not entered as a numbered source in Section 4 because it carries no resolvable identifier (no DOI, PMID, ISBN or registry number for this organization's own PDF, unlike the journal-published guidelines cited above), so none of its content is carried into Section 3 as a citation-backed finding; it is disclosed here, fully, rather than silently dropped, and it informally closes the domain dossier's own §4 gap that the ISFM/IRIS full text was blocked twice on the prior pass.

[inference] Reading [2]'s sampling frame together with [3]'s general-practitioner-oriented guideline design to conclude "this pathway lives mainly in general practice, not referral" is this report's own synthesis of two documents that do not jointly state that conclusion; each is read correctly on its own, and neither states a referral-versus-general-practice split as a measured fact.

6. Claim Candidates